CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

CD70-targeting CAR-T cells

"Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"

Trial Locations (1)

Unknown

RECRUITING

China, Beijing

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Chinese PLA General Hospital

OTHER